Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of those affected by kidney disease, will have CEO John Butler participate in a fireside chat at the H.C. Wainwright Global Investment Conference, scheduled for May 23–26, 2022. An audio replay of the chat will be accessible through Akebia's investor relations webpage starting on May 24 for approximately 90 days. Founded in 2007 and based in Cambridge, Massachusetts, Akebia focuses on developing and commercializing therapeutics for kidney disease.

News Market Reaction – AKBA

+3.47%

+3.47% Session move

In the trading session that priced this news, AKBA gained 3.47%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 19, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which will take place as a hybrid event May 23–26, 2022.

An audio replay of the fireside chat will be available through the Investors section of Akebia's website at https://ir.akebia.com starting on May 24^th and for approximately 90 days following the conference.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact  
Mercedes Carrasco  
Mcarrasco@akebia.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-hc-wainwright-global-investment-conference-301550660.html

SOURCE Akebia Therapeutics

FAQ

When will Akebia Therapeutics participate in the H.C. Wainwright Global Investment Conference?

Akebia Therapeutics will participate in the H.C. Wainwright Global Investment Conference from May 23 to 26, 2022.

Who will represent Akebia Therapeutics at the conference?

CEO John Butler will represent Akebia Therapeutics at the conference.

How can I access the replay of the Akebia Therapeutics fireside chat?

The audio replay will be available on Akebia's investor relations website starting May 24, 2022.

What is the focus of Akebia Therapeutics?

Akebia Therapeutics focuses on developing and commercializing therapeutics for people impacted by kidney disease.